Integrated bioinformatics analysis of differentially expressed genes and immune cell infiltration characteristics in Esophageal Squamous cell carcinoma

## Esophageal Squamous cell carcinoma

1. Esophageal cancer is the seventh most common cancer worldwide, with an estimated 572,034 new cases and 508,585 deaths occurring in 2018.

## Esophageal Squamous cell carcinoma

- 1. Esophageal cancer is the seventh most common cancer worldwide, with an estimated 572,034 new cases and 508,585 deaths occurring in 2018.
- 2. Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of new incident esophageal cancers each year.

## Esophageal Squamous cell carcinoma

- 1. Esophageal cancer is the seventh most common cancer worldwide, with an estimated 572,034 new cases and 508,585 deaths occurring in 2018.
- 2. Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of new incident esophageal cancers each year.
- 3. Due to its inconspicuous symptoms and inadequate endoscopic screening, esophageal cancer is often diagnosed at an advanced stage, and the 5-year overall survival (OS) rate ranges from 12 to 20%

## Aim of the study


1. This study aimed to identify robust DEGs and characterize the immune cell infiltration distribution in ESCC from as many datasets as possible.


# Aim of the study

- 1. This study aimed to identify robust DEGs and characterize the immune cell infiltration distribution in ESCC from as many datasets as possible.
- 2. In addition, a prognostic model for ESCC based on the robust DEGs was established.

# Aim of the study

- 1. This study aimed to identify robust DEGs and characterize the immune cell infiltration distribution in ESCC from as many datasets as possible.
- 2. In addition, a prognostic model for ESCC based on the robust DEGs was established.
- 3. Enrichment analysis and immune infiltration analysis of robust DEGs would improve the understanding of the molecular mechanisms of tumorigenesis and facilitate the development of new therapeutic strategies in ESCC.





GST7351,GSEDAP, GSEDAPI, GSEDA


1. Microarray data collection (Gene Expression Omnibus)

Datasets	Year	Country	Tumor/Normal	Follow-up	Platform	Number of rows
GSE17351	2009	USA	5/5	No	GPL570	54,675
GSE20347	2010	USA	17/17	No	GPL571	22,277
GSE29001	2011	USA	21/24	No	GPL571	22,277
GSE38129	2012	USA	30/30	No	GPL571	22,277
GSE45670	2013	China	28/10	No	GPL570	54,675
GSE53625	2013	China	179/179	Yes	GPL18109	71,584
GSE70409	2013	China	17/17	No	GPL13287	29,187
GSE75241	2015	Brazil	15/15	No	GPL5175	316,919
GSE161533	2020	China	28/28	No	GPL570	54,675

- 1. Microarray data collection
- 2. Differential expression analysis in ESCC (limma + RRA)

```
|log2(FC)| > adjusted p < 0.05
```

RobustRankAggreg package



2

## Robust Rank Aggregation

## Input


#### Snow Attributes Name Type Value list list [3] List of length 3 character [6] Set one 'A' 'B' 'C' 'D' 'E' 'F' character [6] Set two 'A' 'C' 'E' 'B' 'D' 'G' Set three character [6] 'B' 'A' 'E' 'C' 'D' 'H'

### Output


	an   7 Filt	
^	Name	Score
A	Α	0.0468750
В	В	0.3750000
c	С	0.3750000
D	D	0.7324219
E	E	0.7324219
F	F	1.0000000
G	G	1.0000000
н	н	1.0000000

- 1. Microarray data collection
- 2. Differential expression analysis in ESCC
- 3. Functional and pathway enrichment analysis (GO + KEGG)

CC + BP + MF clusterProfileR package




- 1. Microarray data collection
- 2. Differential expression analysis in ESCC
- 3. Functional and pathway enrichment analyses
- 4. Analysis of immune cell infiltration with the CIBERSORT algorithm



CIBERSORTX Home About Contact Menu\* Welcome, Damian Panas\*

### **CIBERS®RTX**


CIBERSORTx is an analytical tool from the Alizadeh Lab and Newman Lab to impute gene expression profiles and provide an estimation of the abundances of member cell types in a mixed cell population, using gene expression data.




Run CIBERSORTx ×


- 1. Microarray data collection
- 2. Differential expression analysis in ESCC
- 3. Functional and pathway enrichment analyses
- 4. Analysis of immune cell infiltration with the CIBERSORT algorithm
- 5. Identification of hub genes

string-db.org
Cytoscape + CytoHubba plugin










#### Browse interactions in tabular form:

<sup>≜</sup> node1	node2	node1 accession	node2 accession	node1 annotation	node2 annotation	score
CDA	DCK	ENSP00000364212	ENSP00000286648	Cytidine deaminase; This enzyme	Deoxycytidine kinase; Required for	0.985
CDA	PNP	ENSP00000364212	ENSP00000354532	Cytidine deaminase; This enzyme	Purine nucleoside phosphorylase;	0.962
CDA	TK1	ENSP00000364212	ENSP00000301634	Cytidine deaminase; This enzyme	Thymidine kinase, cytosolic; Thymi	0.963
CDA	TK2	ENSP00000364212	ENSP00000299697	Cytidine deaminase; This enzyme	Thymidine kinase 2, mitochondrial;	0.942
CDA	TYMP	ENSP00000364212	ENSP00000379038	Cytidine deaminase; This enzyme	Thymidine phosphorylase; May ha	0.996
CDA	UCK1	ENSP00000364212	ENSP00000361285	Cytidine deaminase; This enzyme	Uridine-cytidine kinase 1; Phospho	0.949
CDA	UCK2	ENSP00000364212	ENSP00000356853	Cytidine deaminase; This enzyme	Uridine-cytidine kinase 2; Phospho	0.952
CDA	UCKL1	ENSP00000364212	ENSP00000346155	Cytidine deaminase; This enzyme	Uridine-cytidine kinase-like 1; May	0.970
CDA	UPP1	ENSP00000364212	ENSP00000330032	Cytidine deaminase; This enzyme	Uridine phosphorylase 1; Catalyzes	0.973
CDA	UPP2	ENSP00000364212	ENSP00000474090	Cytidine deaminase; This enzyme	Uridine phosphorylase 2; Catalyzes	0.949


- 1. Microarray data collection
- 2. Differential expression analysis in ESCC
- 3. Functional and pathway enrichment analyses
- 4. Analysis of immune cell infiltration with the CIBERSORT algorithm
- 5. Identification of hub genes
- 6. Analysis of hub genes


Gene Expression Profiling Interactive Analysis (GEPIA) GraphPad Prism 8.0 Tumor Immune Estimation Resource (TIMER)



GEPIA GOPIA Example API Help About GEPIA2 GEPIA2021







Chromosome distribution


### Differential genes by cancer type

Gene Symbol	§ Gene ID	Median (Tumor)	Median (Normal)	Log2(Fold Change)	v adjp (
COL10A1	ENSG00000123500.9	67.461	0.120	5.934	6.52e-208
TEE1	ENSG00000160182.2	133.796	1.270	5.892	2.02e-24
RP11-40C6.2	ENSG00000219928.2	278.049	4.590	5.642	1.98e-85
MMP11	ENSG00000099953.9	167.729	2.560	5.567	9.50e-231
COL11A1	ENSG00000060718.18	37.131	0.500	4.668	1.96e-137
AP000249.2	ENSG00000280178.1	26.150	0.150	4.561	3.61e-121
URE2C	ENSG00000175063.16	54.579	1.410	4.527	1.12e-227
RPS-94035.9	ENSG00000269968.1	17.259	0.000	4.191	1.29e-25
AG83	EN9G00000173467.8	232.904	11.820	4.189	2.97e-24
\$100P	ENSG00000163993.6	48.839	1.880	4.113	1.81e-72

BRCA significantly different genes

### TIMER: Tumor IMmune Estimation Resource

A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells




#### Instruction

Correlation module draws the expression scatterplots between a pair of user-defined genes in a given cancer type, together with the Spearman's rho value and estimated statistical significance. Options for partial correlation conditioned on tumor purity or age are also provided.

- Microarray data collection
- 2. Differential expression analysis in ESCC
- 3. Functional and pathway enrichment analyses
- 4. Analysis of immune cell infiltration with the CIBERSORT algorithm
- 5. Identification of hub genes
- 6. Analysis of hub genes
- 7. Construction and validation of the prognostic model.
- 8. Independence analysis of the prognostic model and construction of the nomogram.

survival package SurvivalROC package rms package



## Results

	Datasets	# of upregulated	# of downregulated
Identification of DEGs and robust DEGs  152 robust DEGs were identified; 54 up- and 98 downregulated (FDR < 0.05)	GSE17351	110	116
	GSE20347	56	163
152 robust DEGs were identified: 54 up. and	GSE29001	168	221
•	GSE38129	38	70
	<u>GSE45670</u>	249	443
	<u>GSE53625</u>	204	482
DEGs ranked according to their log2FC	GSE70409	115	272
values.	GSE75241	124	99
	GSE161533	57	90

2.08	1.58	1.63	1.85	1.73	2.47	1.50	1.75	2.02	MMP1
1.40	1.05	1.51	1.27	1.60	0.36	1.44	1.09	1.30	SPP1
1.40	1.05	1.09	0.79	1.03	1.85	1.22	0.99	1.10	MMP1
0.77	0.70	0.76	0.88	0.73	0.56	1.05	0.86	1.28	LAMC2
1.66	1.32	1.26	0.84	1.28	1.36	1.21	0.65	1.71	MMP12
1.37	1.24	0.76	0.78	0.90	1.83	1.35	1.30	1.25	MMP3
1.27	0.97	0.83	0.86	0.74	0.85	1.11	0.12	1.36	CXCL8
0.86	1.30	0.92	1.42	0.91	1.21	0.10	1.13	0.76	MMP13
0.63	0.63	0.74	0.82	0.77	0.41	0.68	0.61	0.72	LAMB3
0.74	0.83	0.74	0.73	0.76	0.24	0.76	0.99	0.75	PLAU
1.30	0.69	0.98	1.48	1.00	2.09	0.78	1.41	0.06	MAGEA6
0.41	0.59	0.81	0.88	0.87	0.28	0.66	0.85	0.63	CEP55
0.90	1.43	0.85	0.62	1.13	-0.27	1.25	1.09	0.98	CST1
0.44	1.16	0.84	0.77	0.77	0.15	0.96	0.88	0.66	NELL2
0.82	0.72	0.90	0.70	0.85	0.35	0.82	0.85	0.64	PTHLH
0.39	0.76	0.75	0.76	0.72	0.29	0.61	0.64	0.67	FOXM1
0.51	0.85	1.28	1.07	0.97	0.13	0.80	1.07	0.97	ANO1
0.44	0.68	0.71	0.88	0.77	0.37	0.74	0.77	0.61	TPX2
0.50	0.83	0.74	0.78	0.71	0.63	0.77	0.83	0.42	HOXC10
0.40	0.59	0.67	0.65	0.67	0.13	0.57	0.57	0.58	STIL
-1.59	-1.69	-1.63	-1.62	-1.64	-1.79	-1.40	-1.60	-1.54	CRISP3
-0.95	-0.98	-1.12	-1.04	-1.05	-0.25	-1.10	-1.26	-1.14	CLCA4
-0.94	-1.02	-0.94	-1.15	-1.00	-1.02	-1.21	-1.07	-1.16	ENDOU
-1.05	-1.02	-1.13	-0.89	-1.02	-0.41	-1.03	-1.09	-0.97	SCEL
-1.11	-1.03	-1.26	-1.01	-1.29	-0.84	-1.13	-0.91	-1.01	MAL
-0.98	-1.08	-1.05	-0.84	-0.91	-0.42	-0.97	-1.02	-0.96	SPINK5
-0.94	-0.92	-0.94	-0.73	-0.90	-0.20	-0.89	-1.00	-0.74	TMPRSS11E
-0.94	-1.09	-1.04	-0.81	-1.03	-0.74	0.10	-1.29	-1.03	SLURP1
-1.10	-1.33	-1.41	-1.59	-1.32	-0.45	0.10	-1.54	-0.95	CRNN
-0.90	-0.75	-0.73	-0.77	-0.89	-1.55	-1.00	-0.79	-1.02	HPGD
-0.84	-1.00	-0.60	-0.47	-0.75	-0.64	-1.03	-0.74	-0.74	PSCA
-1.06	-1.05	-1.18	-1.00	-1.15	-0.76	-1.07	0.13	-0.86	TGM3
-0.80	-1.02	-1.21	-1.00	-1.16	-0.24	-0.79	-0.99	-0.82	CRCT1
-0.68	-0.87	-0.41	-0.56	-0.49	-0.68	-0.87	-1.04	-0.75	KLK13
-1.03	-0.65	-0.54	-0.84	-0.70	-1.46	-1.35	-0.70	-1.10	GYS2
-0.68	-0.63	-1.13	-0.97	-1.01	-0.61	-0.82	-0.80	-0.70	CLIC3
-0.75	-0.61	-0.63	-0.71	-0.70	-0.51	-0.91	-0.86	-0.92	CWH43
-0.66	-0.62	-0.78	-0.96	-0.63	-0.14	-0.80	-0.62	-0.64	RHCG
-0.54	-0.89	-0.81	-1.12	-0.91	-1.09	-1.10	-0.64	-0.75	CYP4B1
-0.73	-0.72	-0.24	-0.76	-0.33	-1.46	-1.16	-0.60	-0.66	TFAP2B
GSE161533	GSE17351	GSE20347	GSE29001	GSE38129	GSE45670	GSE53625	GSE70409	GSE75241	
1533	351	)347	3001	3129	5670	3625	)409	5241	

2.08	1.58	1.63	1.73	MMP1		5.06	NA	4.84	8.75	MMP1	6
1.40	1.05	1.51	1.60	SPP1	2	4.38	4.37	4.18	3.93	COL11A1	١,
1,40	1.05	1.09	1.03	MMP10		3.16	3.39	3.33	4.13	KRT17	4
0.77	0.70	0.76	0.73	LAMC2	1	3.10	3.28	2.72	4.81	MMP10	
1.66	1,32	1.26	1.28	MMP12		4.63	NA	4.45	4.76	SPP1	2
1.37	1,24	0.76	0.90	MMP3		2.61	3.17	3.34	3.81	COL10A1	
1.27	0.97	0.83	0.74	CXCL8	0	3.67	NA	3,47	5.20	MMP12	0
0.86	1.30	0.92	0.91	MMP13		2.45	3.42	2.37	2.91	MMP13	
0.63	0.63	0.74	0.77	LAMB3		3.20	NA	3.00	4.11	COL1A1	-2
0.74	0.83	0.74	0.76	PLAU	-1	2.38	2.68	2.42	2.61	LAMC2	0.0
1.30	0.69	0.98	1.00	MAGEA6		3.36	NA	2.65	4.26	CXCL8	-4
0.41	0.59	0.81	0.87	CEP55	-2	2.81	NA	2.55	3.34	PTHLH	
0.90	1.43	0.85	1.13	CST1		2.80	NA	2.63	4.77	MAGEA3	-6
0.44	1.16	0.84	0.77	NELL2		2.18	2.58	2.20	2.54	PLAU	
0.82	0.72	0.90	0.85	PTHLH		2.36	2.75	2.24	2.21	MFAP2	
0.39	0.76	0.75	0.72	FOXM1		2.83	NA	2.45	3.66	INHBA	
0.51	0.85	1.28	0.97	ANO1		2.67	NA	2.62	4.30	MAGEA6	
0.44	0.68	0.71	0.77	TPX2		3.78	NA	3.23	2.94	POSTN	
0.50	0.83	0.74	0.71	HOXC10		3.94	NA	3.19	2.36	NTS COL1A2	
0.40	0.59	0.67	0.67	STIL		3.21	NA	2.85	2.56	CRISP3	
-1.59	-1.69	-1.63	-1.64	CRISP3		2.00	1000	-4.37	-3.61	MAL	
-0.95	-0.98	-1.12	-1.05	CLCA4		19,00		-4.47	-3.60	CRNN	
-0.94	-1.02	-0.94	-1.00	ENDOU		5.00	-4.56	-3.20	-3.17	SPINK5	
-1.05	-1.02	-1.13	-1.02	SCEL		-5.34	-4.45	-3.65	-3.10	CLCA4	
-1.11 -0.98	-1.03 -1.08	-1.26 -1.05	-1.29 -0.91	MAL SPINK5		-4.09	-4.07	-3.15	-3.10	PPP1R3C	
-0.94	-0.92	-0.94	-0.91	TMPRSS11E		-4.39	-2.94	-3.45	-3.07	HPGD	
-0.94	-1.09	-1.04		SLURP1		-2.85	-4.55	-3.68	-3.91	ADH1B	
-1.10	-1.33	-1.41	-1.03 -1.32	CRNN		-3.65	-3.97	-2.53	-3.02	TFAP2B	
-0.90	-0.75	-0.73	-0.89	HPGD		-5.36	NA	-3.51	-3.53	SCEL	
-0.90	-1.00	-0.73	-0.75	PSCA		-5.57	NA	-3.94	-3.47	TGM3	
-1.06	-1.05	-1.18	-1.15	TGM3		-4.25	NA	-3.37	-4.00	FLG	
-0.80	-1.03	-1.21	-1.16	CRCT1		-4.05	-4.01	-3.13	-2.53	CYP4B1	
-0.68	-0.87	-0.41	-0.49	KLK13		-3.91	-2.83	-2.78	-2.48	EMP1	
-1.03	-0.65	-0.41	-0.70	GYS2		-4.58	NA	-3.44	-3.05	ENDOU	
-0.68	-0.63	-1.13	-1.01	CLIC3		5.63	NA	-3.94	-2.58	CRCT1	
-0.75	-0.61	-0.63	-0.70	CWH43		-4.59	NA	-3.13	-3.05	TMPRSS11E	
-0.66	-0.62	-0.78	-0.63	RHCG		-5,02	NA	-3.56	-3.04	SLURP1	
-0.54	-0.89	-0.81	-0.91	CYP4B1		-3.11	-3.21	-2.23	-2.38	CYP3A5	
-0.73	-0.72	-0.24	-0.33	TFAP2B		NA	-5:82	NA	-3.69	TMPRSS11B	
						GS	G	G	GS		
GSE161533	GSE17351	GSE20347	GSE38129			E	GSE17351	GSE38129	E		
16.	173	203	38			20	177	88	16		
153	351	47	129			E20347	35	129	E161533		
w						7	-	9	ω		

	1.58	1.63	1.73	MMP1		23.00	NA	444		MMP1	
1.40	1.05	1.51	1.60	SPP1 -	2	2.38	4.37	4.18	3.93	COL11A1	
1.40	1.05	1.09	1.03	MMP10		9.16	3.39	3.33	4.13	KRT17	
0.77	0.70	0.76	0.73	LAMC2 ~	1	3.10	3.28	2.72	100	MMP10	
1.66	1,32	1.26	1.28	MMP12		4.63	NA	4.45	2.10	SPP1	
1.37	1.24	0.76	0.90	MMP3		2.61	3.17	3.34	3.81	COL10A1	
1.27	0.97	0.83	0.74	CXCL8 —	_ 0	3.67	NA	3.47	0.00	MMP12	
0.86	1.30	0.92	0.91	MMP13	_	2,45	3.42	237	2.91	MMP13	
0.63	0.63	0.74	0.77	LAMB3		3.20	ANA.	3.00	4.11	COL1A1	ı
0.74	0.83	0.74	0.76	PLAU -	-1	2.38	2.68	2.42	2.61	LAMC2	
1.30	0.69	0.98	1.00	MAGEA6		3.36	NA	2.65	1.29	CXCL8	
0.41	0.59	0.81	0.87	CEP55	0	2.81	- NA	2.55	3.34	PTHLH	F
0.90	1.43	0.85	1.13	CST1	-2	2,80	NA	2.03	4.22	MAGEA3	341
0.44	1.16	0.84	0.77	NELL2		2.18	2,58	2.20	2.54	-PLAU	
0.82	0.72	0.90	0.85	PTHLH		2.36	2.75	2.24	2.21	MFAP2	
0.39	0.76	0.75	0.72	FOXM1		2.83	NA	2.45	3.66	INHBA	
0.51	0.85	1.28	0.97	ANO1		2.67	NA	2.62	4.30	MAGEA6	
0.44	0.68	0.71	0.77	TPX2		3.78	NA	3.23	2.94	POSTN	
0.50	0.83	0.74	0.71	HOXC10		3.94	NA	3.19	2.36	NTS	
0.40	0.59	0.67	0.67	STIL		3.21	NA	2.85	2.56	COL1A2	
-1.59	-1.69	-1.63	-1.64	CRISP3				-0.00	-0.20	-CRISP3	
-0.95	-0.98	-1.12	-1.05	CLCA4 —		-5,85		-4,37	-3.61	- MAL	
-0.94	-1.02	-0.94	-1.00	ENDOU			-515	-9,47	-3.60	CRNN	
-1.05	-1.02	-1.13	-1.02	SCEL		-5.02	-4.56	3.20	-317	-SPINK5	
-1.11	-1.03	-1.26	-1.29	MAL		.5.34	4,40	-3.65		CLCA4	
-0.98	-1.08	-1.05	-0.91	SPINK5	_	-4.09	-4.07	-3.15	-3.10	PPP1R3C	
-0.94	-0.92	-0.94	-0.90	TMPRSS11E ~	· /	4.39	-2.94	-3.45	The second second	-HPGD	
-0.94	-1.09	-1.04	-1.03	SLURP1 V	$\sim$	-2.86	-4.55	-3.68	-3.91	ADH1B	
-1.10	-1.33	-1.41	-1.32	CRNN -	$\sim$	-0.05	-3.97	-2.53		TFAP2B	
-0.90	-0.75	-0.73	-0.89	HPGD -	1	5.3h	NA	-3.51	3.03	SCEL	
-0.84	-1.00	-0.60	-0.75	PSCA		-0.01	NA	3,94		TGM3	
-1.06	-1.05	-1.18	-1.15	TGM3		-925	NA		-4.00	FLG CVD4B4	
-0.80	-1.02	-1.21	-1.16	CRCT1		-4.05 -3.91	4.01	-3.13	2.53	CYP4B1	
-0.68	-0.87	-0.41	-0.49	KLK13		No. of Concession, Name of	_	3/8	-3.05	EMP1 ENDOU	
-1.03	-0.65	-0.54	-0.70	GYS2		-4.58	NA	2.04	-3,05	CRCT1	
-0.68	-0.63	-1.13	-1.01	CLIC3	80	0 03	NA NA	-3.94	-200 200	TMPRSS11E	
-0.75	-0.61	-0.63	-0.70	CWH43		9.59 5.00	NA NA	-3.13	-3.04	SLURP1	
-0.66	-0.62	-0.78	-0.63	RHCG		-3.11	-3.21	-2.23	-2.38	CYP3A5	
-0.54	-0.89	-0.81	-0.91	CYP4B1		-5.11 NA	-5.21	-2.23 NA	-3.69	TMPRSS11B	
-0.73	-0.72	-0.24	-0.33	TFAP2B			30000		G	LIMILITAGITE	
SS	SS	SS	GSE38129			GSI	GSI	GSE38129	S		
E16	Ξ.	E20	E3			E2	E	E	Ξ.		
GSE161533	GSE17351	GSE20347	812			E20347	17351	81	61.		
ಜ	2	7	Ø			47	51	29	E161533		

Many biological functions enriched with the DEGs were associated with the tumor microenvironment (TME) and growth of cancer cells

Many biological functions enriched with the DEGs were associated with the tumor microenvironment (TME) and growth of cancer cells

BP: extracellular matrix organization, extracellular structure organization and leukocyte chemotaxis

Many biological functions enriched with the DEGs were associated with the tumor microenvironment (TME) and growth of cancer cells

BP: extracellular matrix organization, extracellular structure organization and leukocyte chemotaxis

CC: collagen-containing extracellular matrix, apical part of cell and endoplasmic reticulum lumen

Many biological functions enriched with the DEGs were associated with the tumor microenvironment (TME) and growth of cancer cells

BP: extracellular matrix organization, extracellular structure organization and leukocyte chemotaxis

CC: collagen-containing extracellular matrix, apical part of cell and endoplasmic reticulum lumen

MF: receptor ligand activity, signaling receptor activator activity, extracellular matrix structural, cytokine activity and CXCR chemokine receptor binding


Many biological functions enriched with the DEGs were associated with the tumor microenvironment (TME) and growth of cancer cells


BP: extracellular matrix organization, extracellular structure organization and leukocyte chemotaxis


CC: collagen-containing extracellular matrix, apical part of cell and endoplasmic reticulum lumen


MF: receptor ligand activity, signaling receptor activator activity, extracellular matrix structural, cytokine activity and CXCR chemokine receptor binding

KEGG: IL-17 signaling pathway, cytokine-cytokine receptor interaction, ECM – receptor interaction and TNF signaling pathway









### Immune infiltration


The CIBERSORT algorithm was used to analyse immune cell infiltration in all 665 samples from the 9 GEO normalized expression matrices

Seven types of immune cells were more abundant in ESCC tissues:

- naïve CD4<sup>+</sup> T cells,
- 2. activated memory CD4<sup>+</sup> T cells
- 3. follicular helper T cells
- 4. resting natural killer (NK) cells
- 5. M0 macrophages
- 6. M1 macrophages
- 7. activated dendritic cells

Six types of immune cells were more abundant in normal tissues:

- 1. naïve B cells
- 2. resting memory CD4<sup>+</sup> T cells
- 3. gamma delta T cells
- 4. M2 macrophages
- 5. resting dendritic cells
- 6. resting mast cells



## Protein-protein interaction


To further study the interaction of the 152 robust DEGs, we constructed a PPI network using the Search Tool for the Retrieval of Interacting Genes (STRING) database with a combined score > 0.4 as the cutoff criterion.

## Protein-protein interaction

To further study the interaction of the 152 robust DEGs, we constructed a PPI network using the Search Tool for the Retrieval of Interacting Genes (STRING) database with a combined score > 0.4 as the cutoff criterion.

### Nine identified hub genes:


- 1. cytidine deaminase (CDA)
- 2. chemokine ligand 1 (CXCL1)
- 3. insulin-like growth factor binding protein 3 (IGFBP3)
- 4. matrix metallopeptidase 3 (MMP3)
- 5. matrix metallopeptidase 11 (MMP11)
- 6. plasminogen activator urokinase (PLAU, also named uPA)
- 7. serpin peptidase inhibitor member 1 (SERPINE1)
- 8. secreted phosphoprotein 1 (SPP1)
- 9. versican (VCAN)




## Validation of hub genes


The mRNA expression of the 9 hub genes was validated using the Gene Expression Profiling Interactive Analysis (GEPIA) database.

Consistent with the results of the GEO analysis, the mRNA expression of CXCL1, IFGFBP3, MMP3, MMP11, PLAU, SERPINE1, SPP1 and VCAN was markedly upregulated but the mRNA expression of CDA was markedly downregulated in esophageal carcinoma tissues (*P* < 0.01)












Our results showed that the expression levels of CDA (Cor = -0.27) and CXCL1 (Cor = -0.177) were negatively associated with the macrophage infiltration level.

In contrast, those of IGFBP3 (Cor = 0.342), MMP11 (Cor = 0.397), PLAU (Cor = 0.146), SERPINE1 (Cor = 0.208), SPP1 (Cor = 0.353) and VCAN (Cor = 0.576) were positively associated with the macrophage infiltration level.







# Prognostic model

To investigate the prognostic significance of the 152 robust DEGs, 17 survival-related genes (P < 0.05) were identified by univariate Cox regression analysis in the GSE53625 datase.

After selecting the most suitable combination of candidate genes by multiple stepwise Cox regression, seven genes were used to construct a prognostic model:

- 1. interleukin 18 (IL18)
- 2. PLAU
- 3. anoctamin 1 (ANO1)
- 4. solute carrier organic anion transporter family member 1B3 (SLCO1B3)
- 5. cystatin SN (CST1)
- 6. neural EGFL like 2 (NELL2)
- 7. melanoma antigen family A11 (MAGEA11)

# Prognostic model

To validate the risk model constructed with the 179 patients in GSE53625, we selected 185 patients in TCGA as the validation cohort. The patients in the two cohorts were divided into the low-risk and high-risk groups according to the median risk score. Kaplan–Meier survival analysis demonstrated that in both cohorts, the prognosis of the low-risk group was significantly better than that of the high-risk group.




Figure S1




Figure S2

